
HCAT Stock Forecast & Price Target
HCAT Analyst Ratings
Bulls say
Health Catalyst Inc. has demonstrated a strong upward trajectory in earnings power over the past seven years, characterized by increasing EBITDA and a growing client base, alongside a reduction in headcount, which suggests improved operational efficiency. Positive sentiment from healthcare executives indicates that demand for Health Catalyst's modules is rising, as they report better-than-expected patient volumes and an increase in purchases. Furthermore, as the acute care market begins to recover from previous inflationary pressures and staffing challenges, the anticipated increase in demand for Health Catalyst's solutions and services positions the company favorably for continued revenue growth and improved margins.
Bears say
Health Catalyst Inc has experienced a slowdown in total revenue growth, raising concerns about future revenue and EBITDA growth as the total addressable market appears highly penetrated. Despite a modest revenue and EBITDA beat in the third quarter and maintained guidance, the company faces potential sequential revenue declines and a downward revision in the 2026 revenue outlook, suggesting ongoing financial challenges. Additionally, pressures on margins, declines in net dollar-based retention, and a challenging hospital buying environment amplify the negative outlook for Health Catalyst’s stock.
This aggregate rating is based on analysts' research of Health Catalyst Inc and is not a guaranteed prediction by Public.com or investment advice.
HCAT Analyst Forecast & Price Prediction
Start investing in HCAT
Order type
Buy in
Order amount
Est. shares
0 shares